New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023. Drug prices have been the subject of intense interest among policymakers in Washington. In the search for solutions, Congress has recently focused on pharmacy benefit managers (PBMs) and the rebates that PBMs negotiate on behalf of health insurance companies and large employers. Consistent with other research, MGA’s latest analysis finds that rebates are not associated with list price increases. In fact, among the drugs with the largest price increases, 9 out of 10 did not have rebates.
Read the full report here.
